DGAP-News

Epigenomics AG: Epigenomics Announces Completion of Enrollment in Epi proColon(R) ADMIT Trial - Seite 2

ever, we look forward to having the opportunity of offering screening
eligible adults in the United States an easy, non-invasive option for
regular colorectal cancer screening once we receive approval from the FDA."

Contact Epigenomics AG

Antje Zeise, Manager IR | PR
Epigenomics AG
Geneststraße 5
10829 Berlin
Tel [phone]
[e-mail]
www.epigenomics.com

For US press inquiries:

Epigenomics, Inc.
20271 Goldenrod Lane, Suite 2027
Germantown, Maryland 20876
[e-mail]

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing innovative products for cancer. The
Company's products enable doctors to diagnose cancer earlier and more
accurately, leading to improved outcomes for patients. Epigenomics' lead
product, Epi proColon(R), is a blood-based test for the early detection of
colorectal cancer, which is currently marketed in Europe, has received
approval by the Chinese Food and Drug Administration for China and is under
regulatory review by the U.S. Food and Drug Administration (FDA).
Additionally, the Company markets its tissue assay for use in lung cancer
diagnosis, Epi proLung(R), in Europe. The Company's technology and products
have been validated through multiple partnerships with leading global
diagnostic companies and testing laboratories. Epigenomics is an
international company with operations in Europe and the U.S.A.
Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.

The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.



---------------------------------------------------------------------

25.03.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: Epigenomics AG
Geneststraße 5
10829 Berlin
Germany
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.epigenomics.com
ISIN: DE000A11QW50
WKN: A11QW5
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart


End of News DGAP News-Service
---------------------------------------------------------------------
337025 25.03.2015